About Cytohesin-4
Cytohesin-4 (CYTH4) is a protein
from Homo sapiens identified by UniProt accession
Q9UIA0, 394 residues long.
MolForge cross-references it against 0 known binders and
45 disease associations.
Target properties
| Protein name | Cytohesin-4 |
|---|
| UniProt accession | Q9UIA0 |
|---|
| Gene | CYTH4 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 394 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (45)
Diseases linked to this target (Open Targets).
- uterine fibroid · score 0.23
- blood protein measurement · score 0.15
- inflammatory bowel disease · score 0.12
- acute myeloid leukemia · score 0.08
- 46,XY complete gonadal dysgenesis · score 0.05
- platelet component distribution width · score 0.04
- mean platelet volume · score 0.04
- 46,XX testicular disorder of sex development · score 0.04
- platelet count · score 0.04
- hemochromatosis type 5 · score 0.03
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q9UIA0-F1 | alphafold | PREDICTED | 86.94 | — |
Amino-acid sequence (394 residues)
MDLCHPEPAE LSSGETEELQ RIKWHRKQLL EDIQKLKDEI ADVFAQIDCF ESAEESRMAQ KEKELCIGRK KFNMDPAKGI QYFIEHKLLT PDVQDIARFL YKGEGLNKTA IGTYLGERDP INLQVLQAFV DCHEFANLNL VQALRQFLWS FRLPGEAQKI DRMMEAFATR YCLCNPGVFQ STDTCYVLSF SIIMLNTSLH NPNVRDRPPF ERFVSMNRGI NNGSDLPEDQ LRNLFDSIKS EPFSIPEDDG NDLTHTFFNP DREGWLLKLG GRVKTWKRRW FILTDNCLYY FEFTTDKEPR GIIPLENLSV QKVDDPKKPF CLELYNPSCR GQKIKACKTD GDGRVVEGKH ESYRISATSA EERDQWIESI RASITRVPFY DLVSTRKKKI ASKQ
Explore Cytohesin-4 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets